Corporate$JNJ9:48 AM ET

Johnson & Johnson model analysis supports TECVAYLI plus DARZALEX FASPRO for early-line myeloma

By BORSA NewsroomPublished Sep 23, 2026, 9:48 AM EDTUpdated Sep 24, 2026, 5:04 PM EDT

A new model-based analysis from Johnson & Johnson suggests TECVAYLI plus DARZALEX FASPRO could improve long-term survival in patients with early-line relapsed/refractory multiple myeloma. The analysis adds to existing clinical data supporting the combination.

Sentimentbullish 65

Bullish · 65 of 100

Impact25

low · stays off the top drivers

Confidence80%

high confidence · single wire

Eventdeveloping

v1 · alerts feed only

WHAT WE KNOW

Johnson & Johnson released a model-based analysis supporting TECVAYLI plus DARZALEX FASPRO in early-line relapsed/refractory multiple myeloma.